Table 1.
Clinical characteristics by early eGFR decline groups (n=8526)
| Characteristic | <− 20% | −20% to <−10% | −10% to <10% | 10% to <20% | ≥20% | P Value |
|---|---|---|---|---|---|---|
| n=623 (7.3%) | n=1103 (13.0%) | n=4547 (53.3%) | n=1393 (16.3%) | n=860 (10.1%) | ||
| ∆eGFR (%) | −28.3±8.3 | −14.3±2.8 | 0.1±5.5 | 14.5±2.9 | 30.7±12.8 | |
| ∆eGFR (ml/min per 1.73 m2) | −21.1±10.4 | −10.7±3.9 | 0.0±4.1 | 10.0±3.4 | 18.9±7.8 | |
| Baseline MDRD eGFR (ml/min per 1.73 m2) | 74±25 | 75±22 | 73±19 | 69±19 | 63±18 | <0.001 |
| Baseline age (year) | 68.4±9.7 | 67.8±9.4 | 67.8±9.3 | 68.0±9.2 | 67.1±9.3 | 0.095 |
| Female (%) | 35 | 33 | 33 | 37 | 42 | <0.001 |
| Black (%) | 34 | 32 | 31 | 28 | 32 | 0.025 |
| Never smoked (%) | 42 | 44 | 44 | 45 | 44 | 0.60 |
| Intensive SBP group (%) | 70 | 60 | 49 | 42 | 41 | <0.001 |
| Baseline SBP, mm Hg | 146±17 | 143±15 | 139±15 | 137±15 | 135±15 | <0.001 |
| Baseline DBP, mm Hg | 79±13 | 79±12 | 78±12 | 77±11 | 76±12 | <0.001 |
| ∆SBP (6 mo–baseline) (mm Hg) | −24±20 | −18±18 | −11±18 | −6±18 | −3±20 | <0.001 |
| ∆DBP (6 mo–baseline) (mm Hg) | −12±12 | −9±11 | −6±11 | −4±10 | −2±12 | <0.001 |
| Baseline CKD (%) | 30 | 26 | 25 | 31 | 43 | <0.001 |
| Baseline CVD (%) | 20 | 20 | 20 | 18 | 19 | 0.54 |
| Baseline Framingham 10-yr risk score | 25 (17–36) | 24 (17–34) | 22 (15–32) | 21 (15–30) | 20 (14–28) | <0.001 |
| Baseline urine ACR, mg/g | 14 (7–42) | 11 (6–26) | 9 (6–20) | 8 (5–17) | 9 (5–18) | <0.001 |
Data are presented as mean±SD or median (interquartile range) for continuous measures and percent for categorical measures. ∆SBP, change in SBP; ∆DBP, change in DBP; ACR, albumin-to-creatinine ratio.